D.C. Diagnosis is STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.

First In STAT: CSRxP ups its fight with pharma over R&D

The Campaign for Sustainable Rx Pricing is attacking pharma with a new study, first shared with STAT, that finds 10 of the largest drug makers spent on average 22% of their revenues on research and development in 2017 — a figure the group says proves pharma “is investing more boldly in profits, advertising and corporate overhead than in researching new cures.” The study also provides some interesting new data on how much drug makers spend on advertising and marketing, based on proprietary data from the firm GlobalData. STAT has all the details of the study here, but I wanted to highlight a few data points that caught my eye:

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy